anti-PD-L1 monoclonal antibody
Showing 1 - 25 of >10,000
Extensive Stage Small Cell Lung Cancer Trial in Shanghai (recombinant anti-PD-L1 mAb injection combined with carboplatin and
Recruiting
- Extensive Stage Small Cell Lung Cancer
- recombinant anti-PD-L1 monoclonal antibody injection combined with carboplatin and etoposide
-
Shanghai, Shanghai, ChinaShanghai Chest Hospital
May 9, 2022
Solid Tumors, Adult Trial in Kaunas (NECVAX-NEO1)
Recruiting
- Solid Tumors, Adult
- NECVAX-NEO1
-
Kaunas, LithuaniaElona Juozaityte
May 16, 2022
Colon Tumor Trial in Hangzhou (Oxaliplatin, Capecitabine, Anti-PD-L1 Monoclonal Antibody)
Not yet recruiting
- Colon Neoplasm
- Oxaliplatin
- +4 more
-
Hangzhou, Zhejiang, ChinaSecond Affiliated Hospital of Zhejiang University School of Medi
Jun 25, 2023
Local Progression or Metastatic Melanoma With Failed First-line Treatment Trial in Beijing (Pexa-Vec combined with ZKAB001,
Recruiting
- Local Progression or Metastatic Melanoma With Failed First-line Treatment
- Pexa-Vec combined with ZKAB001
- ZKAB001 monotherapy
-
Beijing, ChinaBeijing Cancer Hospital
Mar 30, 2022
Recurrent Non-Small Cell Lung Carcinoma, Stage IV NSCLC Trial in Sacramento (Anti-PD-L1 Monoclonal Antibody MPDL3280A,
Terminated
- Recurrent Non-Small Cell Lung Carcinoma
- Stage IV Non-Small Cell Lung Cancer
- Anti-PD-L1 Monoclonal Antibody MPDL3280A
- Stereotactic Body Radiation Therapy
-
Sacramento, CaliforniaUniversity of California Davis
Aug 2, 2022
Clinical Stage III Cutaneous Melanoma AJCC v8, Melanoma, Metastatic Melanoma Trial in Rochester (Anti-PD-L1 Monoclonal Antibody
Recruiting
- Clinical Stage III Cutaneous Melanoma AJCC v8
- +3 more
- Anti-PD-L1 Monoclonal Antibody IMC-001
- Punch Biopsy
-
Rochester, MinnesotaMayo Clinic in Rochester
Jan 4, 2023
Melanoma, Head and Neck Squamous Cell Carcinoma Trial in Helsinki (TILT-123, Avelumab)
Recruiting
- Melanoma
- Head and Neck Squamous Cell Carcinoma
- TILT-123
- Avelumab
-
Helsinki, FinlandDocrates Cancer Center
Jul 12, 2022
Solid Tumor Trial in Richmond (Stereotactic radiotherapy, Biological: humanized anti-PD-1 mAb, Biological: humanized anti-PD-L1
Completed
- Solid Tumor
- Stereotactic radiotherapy
- +2 more
-
Richmond, VirginiaVirginia Commonwealth University/Massey Cancer Center
Dec 20, 2021
Unresectable Clinical Stage III Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Merkel Cell Carcinoma AJCC v8, Merkel Cell
Not yet recruiting
- Unresectable Clinical Stage III Merkel Cell Carcinoma AJCC v8
- +2 more
- Biopsy
- +6 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Sep 28, 2023
Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for
Recruiting
- Hepatocellular Carcinoma Non-resectable
- HAIC
- +8 more
-
Quanzhou, Fujian, China
- +1 more
Jan 26, 2023
Advanced Solid Tumors Trial in Australia, New Zealand, Spain (BGB-A333, BGB-A317)
Terminated
- Advanced Solid Tumors
-
Clayton, Victoria, Australia
- +7 more
Oct 12, 2021
Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for
Recruiting
- Hepatocellular Carcinoma Non-resectable
- TACE
- +8 more
-
Quanzhou, Fujian, China
- +3 more
Jan 29, 2023
Cervical Cancer Trial in Wuhan (Recombinant humanized anti-PD-1 mAb injection, Cisplatin, Bevacizumab Injection)
Not yet recruiting
- Cervical Cancer
- Recombinant humanized anti-PD-1 monoclonal antibody injection
- +4 more
-
Wuhan, Hubei, ChinaTongji Hospital affiliated to Tongji Medical College of Huazhong
Nov 3, 2023
Advanced Malignant Tumor Trial in Shanghai (Human Anti-PD-L1 Monoclonal Antibody Injection (LDP) Combined with Recombinant
Recruiting
- Advanced Malignant Tumor
- Human Anti-PD-L1 Monoclonal Antibody Injection (LDP) Combined with Recombinant Anti-EGFR Human Mouse Chimeric Monoclonal Antibody Injection (CDP1)
-
Shanghai, Shanghai, ChinaDragonboat Biopharmaceutical,Co.,Ltd
Feb 3, 2021
Lymphoma, T-Cell Trial in Charlottesville (Durvalumab, Pralatrexate, Romidepsin)
Recruiting
- Lymphoma, T-Cell
- Durvalumab
- +3 more
-
Charlottesville, VirginiaUniversity of Virginia
Mar 16, 2022
Metastatic Non-Small Lung Cell Cancer, Recurrent Non-Small Lung Cell Cancer, Stage IV Lung Cancer AJCC v8 Trial in Atlanta
Recruiting
- Metastatic Non-Small Lung Cell Cancer
- +4 more
- Docetaxel
- +2 more
-
Atlanta, GeorgiaWinship Cancer Institute of Emory University
Oct 19, 2022
Skin Health and Quality of Life in Patients Receiving
Not yet recruiting
- Lung Cancer
- +7 more
- EQ-5D-5L questionnaire
- +2 more
-
Roma, ItalyRoberto Iacovelli
May 17, 2023